Mohanna, M.
Roberts, E.
Whitty, L.
Gritzfeld, J. F.
Pain, C. E.
Girschick, H. J.
Preston, J.
Hadjittofi, M.
Anderson, C.
Ferguson, P. J.
Theos, A.
Hedrich, C. M.
Funding for this research was provided by:
CRMO Foundation
NIHR/Versus Arthritis CSG
Alder Hey Children's Charity
Article History
Received: 8 May 2023
Accepted: 16 June 2023
First Online: 30 June 2023
Declarations
:
: All participants provided written informed consent for the participation in the surveys and publication of results. Ethics approval was not necessary and has been discussed with our local patient and public in involvement and engagement group (JP).
: All participants provided written informed consent for the participation in the surveys and publication of results. Ethics approval was not necessary and has been discussed with our local patient and public in involvement and engagement group (JP).
: CMH, PJF, and HJG participated in advisory boards on the use of canakinumab in inflammatory bone disease hosted by Novartis.